A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections
Public ClinicalTrials.gov record NCT07232004. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A First-in-Human, Phase 1a/b, Single-Dose and Multiple-Dose Study of ABBV-547 to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability in Adult Participants and Efficacy in Adult Participants
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess how safe, effective, and tolerable ABBV-547 is in adult participants in the United States and Japan. There will be 2 parts to this study. In Part 1, participants are placed in one of 7 groups where they will receive ABBV-547 at different doses or placebo. There is a 1 in 4 chance participants will receive placebo. In Part 2, participants are placed in one of 4 groups where they will receive ABBV-547 at different doses or placebo. There is a 1 in 7 chance participants will receive placebo. Group 11 is the only group that will receive multiple doses. Approximately 142 adult participants will be enrolled at approximately 21 sites in the United States and Japan. Participants will be administered one dose or multiple doses of ABBV-547 or placebo. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Study identification
- NCT ID
- NCT07232004
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 142 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 24, 2025 (Actual)
- Primary completion
- May 2028 (Estimated)
- Completion
- May 2028 (Estimated)
- Last update posted
- Oct 15, 2026
2025 – 2028
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Total Dermatology /ID# 279798 | Birmingham | Alabama | 35203-4024 | — |
| Dermatology Trial Associates /ID# 279984 | Bryant | Arkansas | 72022 | — |
| CenExel Act- Anaheim Clinical Trials /ID# 279612 | Anaheim | California | 92801 | — |
| Dermatology Research Associates - Los Angeles /ID# 279383 | Los Angeles | California | 90045 | — |
| Integrative Skin Science and Research - Location 2 /ID# 279386 | Sacramento | California | 95815 | — |
| Wellness Clinical Research - Miami Lakes /ID# 279803 | Miami Lakes | Florida | 33016 | — |
| Advanced Clinical Research Institute - Tampa /ID# 279342 | Tampa | Florida | 33607 | — |
| Acpru /Id# 278638 | Grayslake | Illinois | 60030 | — |
| MetroBoston Clinical Partners /ID# 279992 | Boston | Massachusetts | 02135 | — |
| Minnesota Clinical Study Center /ID# 279987 | New Brighton | Minnesota | 55112 | — |
| MediSearch Clinical Trials /ID# 279416 | Saint Joseph | Missouri | 64506 | — |
| Skin Specialists /ID# 279531 | Omaha | Nebraska | 68144 | — |
| The Skin Center Dermatology Group. /ID# 279983 | New City | New York | 10956-7153 | — |
| Equity Medical, LLC - Bronx /ID# 279808 | The Bronx | New York | 10455 | — |
| Oregon Dermatology and Research Center /ID# 279391 | Portland | Oregon | 97210 | — |
| Health Concepts /ID# 279529 | Rapid City | South Dakota | 57702 | — |
| Center for Clinical Studies - Houston - Binz Street /ID# 279419 | Houston | Texas | 77004 | — |
| Austin Institute for Clinical Research - Pflugerville /ID# 279387 | Pflugerville | Texas | 78660 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07232004, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07232004 live on ClinicalTrials.gov.